A physiologic imaging pilot study of breast cancer treated with AZD2171

Clinical Cancer Research

Volumn 12, Issue 1, 2006, Pages 281-288

  Miller, Kathy D ^a   Miller, Michael ^a   Mehrotra, Sanjana ^a   Agarwal, Beamon ^a   Mock, Bruce H ^a   Zheng, Qi Huang ^a   Badve, Sunil ^a   Hutchins, Gary D ^a   Sledge Jr , George W ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; CARBON MONOXIDE; FLUORODEOXYGLUCOSE F 18; FLUOROMETHANE F 18; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 2 RECEPTOR TYROSINE KINASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER SIZE; CELL STRAIN MCF 7; CONTROLLED STUDY; DIAGNOSTIC IMAGING; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR BLOOD FLOW; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; MICE; NEOVASCULARIZATION, PATHOLOGIC; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; QUINAZOLINES; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 31544436073     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0219     Document Type: Article

References (50)

1. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
2. Gasparini G. Angiogenesis in breast cancer. Role in biology, tumor progression, and prognosis. In: Bowcock A, editor. Breast cancer: molecular genetics, pathogenesis, and therapeutics. Totowa (NJ): Humana Press Inc.; 1999. p. 347-71.
3. Relf M, LeJeune S, Scott PA, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997;57:963-9.
4. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocrinol Rev 1997;18:1-22.
5. Neufeld G, Kessler O, Herzog Y. The interaction of neuropilin-1 and neuropilin-2 with tyrosine-kinase receptors for VEGF. Adv Exp Med Biol 2002;515:81-90.
6. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascularendothelial growth factor. Cell 1998;92:735-45.
7. Cai J, Ahmad S, Jiang WG, et al. Activation of vascular endothelial growth factor receptor-1 sustains angiogenesis and Bcl-2 expression via the phosphatidylinositol 3-kinase pathway in endothelial cells. Diabetes 2003;52:2959-68.
8. Brekken RA, Overholser JP, Stastny VA, Waltenberger J, Minna JD, Thorpe PE. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res 2000;60:5117-24.
9. Skobe M, Hawighorst T, Jackson DG, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001;7:192-8.
10. Kadambi A, Carreira CM, Yun CO, et al. Vascular endothelial growth factor (VEGF)-C differentially affects tumor vascular function and leukocyte recruitment: role of VEGF-receptor 2 and host VEGF-A. Cancer Res 2001;61:2404-8.
11. Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005;65:4389-400.
12. Drevs J, Medinger M, Mross K, et al. Phase I clinical evaluation of A2D2171, a highly potent VEGF receptor tyrosine kinase inhibitor, in patients with advanced cancer. Proc Am Soc Clin Oncol 2005;23:192s.
13. Ryan C, Stadler W, Roth B, Ouchalski T, Koehler M, Small E. Safety and tolerability of AZD2171, a highly potent VEGF inhibitor, in patients with advanced prostate adenocarcinoma Proc Am Soc Clin Oncol 2005;23:204s.
14. McLeskey SW, Tobias CA, Vezza PR, Filie AC, Kern FG, Hanfelt J. Tumor growth of FGF or VEGF transfected MCF-7 breast carcinoma cells correlates with density of specific microvessels independent of the transfected angiogenic factor. Am J Pathol 1998;153:1993-2006.
15. Kern FG, McLeskey SW, Zhang L, et al. Transfected MCF-7 cells as a model for breast cancer progression Breast Cancer Res Treat 1994;31:153-65.
16. Kearfott KJ. Absorbed dose estimates for positron emission tomography (PET): C15O, 15CO, CO15O. J Nucl Med 1982;23:1031-7.
17. Phelps ME, Huang SC, Hoffman EJ, Kuhl DE. Validation of tomographic measurement of cerebral blood volume with C11-labeled carboxyhemoglobin. J Nucl Med 1979;20:328-34.
18. 18F- fluoromethane for cerebral blood flow measurement with PET. Nuklearmedizin 1990;29:84.
19. Holden JE, Gatley SJ, Hichwa RD, et al. Cerebral blood flow using PET measurements of fluoromethane kinetics. J Nucl Med 1981;22:1084-8.
20. Rouze N, Hutchins G. Design and characterization of Indy PET-II: a high resolution, high-sensitivity dedicated research scanner. IEEE Trans Nucl Sci 2003;50:1491-7.
21. 18F] fluoromethane. Int J Rad Appl Instrum 1991;42:1049-53.
22. 18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986;27:235-8.
23. Huang S, Carson R, Phelps M. Measurement of local blood flow and distribution volume with short-lived isotopes: a general input technique. J Cereb Blood Flow Metab 1982;2:99-108.
24. Kety S, Schmidt C. The nitrous oxide method for the quantitative determination of cerebral blood flow in man: theory, procedure, and normal values. J Clin Invest 1948;27:476-83.
25. Tynninen O, Sjostrom J, von Boguslawski K, et al. Tumour microvessel density as predictor of chemotherapy response in breast cancer patients. Br J Cancer 2002;86:1905-8.
26. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early stage breast carcinoma. J Natl Cancer Inst 1992;84:1875-87.
27. Rubio L, Burgos JS, Morera C, Vera-Sempere FJ. Morphometric study of tumor angiogenesis as a new prognostic factor in nasopharyngeal carcinoma patients. Pathol Oncol Res 2000;6:210-6.
28. Diallo R, Schaefer KL, Bankfalvi A, et al. Secretory carcinoma of the breast: a distinct variant of invasive ductal carcinoma assessed by comparative genomic hybridization and immunohistochemistry. Hum Pathol 2003;34:1299-305.
29. 15O-water for monitoring prostate cancer during a phase II anti-angiogenic drug trial with thalidomide. Clin Positron Imaging 2000;3:144.
30. Logan TF, Jadali F, Egorin MJ, et al. Decreased tumor blood flow as measured by positron emission tomography in cancer patients treated with interleukin-1 and carboplatin on a phase I trial. Cancer Chemother Pharmacol 2002;50:433-44.
31. Wells P, Jones T, Price P. Assessment of inter- and intrapatient variability in C1502 positron emission tomography measurements of blood flow in patients with intra-abdominal cancers. Clin Cancer Res 2003;9:6350-6.
32. Anderson H, Yap JT, Wells P, et al. Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane. Br J Cancer 2003;89:262-7.
33. Critical determinants in cancer progression and metastasis. A centennial celebration of Dr. Stephen Paget's "seed and soil" hypothesis. Cancer Metastasis Rev 1989;8:93-197.
34. Viadana E, Au KL. Patterns of metastases in adenocarcinomas of man. An autopsy study of 4,728 cases. J Med 1975;6:1-14.
35. Fidler IJ, Naito S, Pathak S. Orthotopic implantation is essential for the selection, growth and metastasis of human renal cell cancer in nude mice [corrected]. Cancer Metastasis Rev 1990;9:149-65.
36. Gohongi T, Fukumura D, Boucher Y, et al. Tumor-host interactions in the gallbladder suppress distal angiogenesis and tumor growth: involvement of transforming growth factor β1. Nat Med 1999;5:1203-8
37. Tsuzuki Y, Carreira CM, Bockhorn M, Xu L, Jain RK, Fukumura D. Pancreas microenvironment promotes VEGF expression and tumor growth: novel window models for pancreatic tumor angiogenesis and microcirculation. Lab Invest 2001;81:1439-51.
38. Gohongi T, Todoroki T, Fukumura D, Jain RK. Influence of the site of human gallbladder xenograft (Mz-ChA-1) on angiogenesis at the distant site. Oncol Rep 2004;11:803-7.
39. Jain RK. Normalizing tumor vasculature with antiangiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-9.
40. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression [see comments]. Nat Med 1995;1:149-53.
41. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
42. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration Cancer Res 2002;62:4645-55
43. Fong TA, Shawver LK, Sun L, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999;59:99-106
44. 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 2001;42:9-16.
45. Bos R, van Der Hoeven JJ, van Der Wall E, et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002;20:379-87.
46. Zasadny KR, Tatsumi M, Wahl RL. FDG metabolism and uptake versus blood flow in women with untreated primary breast cancers. Eur J Nucl Med Mol Imaging 2003;30:274-80.
47. Mankoff DA, Dunnwald LK, Gralow JR, et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med 2002;43:500-9.
48. Mankoff DA, Dunnwald LK, Gralow JR, et al. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med 2003;44:1806-14.
49. Miller K, Hutchins G, Miller M, Badve S, Sledge G. ZD6474-mediated vascular changes in a breast cancer xenograft model illustrated by positron emission tomography. AACR-NCI-EORTC Conference, November 19, 2003. Boston, MA.
50. Miller KD, Hutchins GD, Miller M, Badve S, Murray L, Sledge GW. The search for surrogates-physiologic imaging in a breast cancer xenograft model during treatment with SU11248. Breast Cancer Res Treat 2003;77:S18.